This paper describes the development and characterization of a microphysiology platform for drug safety and efficacy in liver models of disease that includes a human, 3D, microfluidic, four-cell, sequentially layered, self-assembly liver model (SQL-SAL); fluorescent protein biosensors for mechanistic readouts; as well as a microphysiology system database (MPS-Db) to manage, analyze, and model data. The goal of our approach is to create the simplest design in terms of cells, matrix materials, and microfluidic device parameters that will support a physiologically relevant liver model that is robust and reproducible for at least 28 days for stand-alone liver studies and microfluidic integration with other organs-on-chips. The current SQL-SAL uses primary human hepatocytes along with human endothelial (EA.hy926), immune (U937) and stellate (LX-2) cells in physiological ratios and is viable for at least 28 days under continuous flow. Approximately, 20% of primary hepatocytes and/or stellate cells contain fluorescent protein biosensors (called sentinel cells) to measure apoptosis, reactive oxygen species (ROS) and/or cell location by high content analysis (HCA). In addition, drugs, drug metabolites, albumin, urea and lactate dehydrogenase (LDH) are monitored in the efflux media. Exposure to 180 mM troglitazone or 210 mM nimesulide produced acute toxicity within 2-4 days, whereas 28 mM troglitazone produced a gradual and much delayed toxic response over 21 days, concordant with known mechanisms of toxicity, while 600 mM caffeine had no effect. Immune-mediated toxicity was demonstrated with trovafloxacin with lipopolysaccharide (LPS), but not levofloxacin with LPS. The SQL-SAL exhibited early fibrotic activation in response to 30 nM methotrexate, indicated by increased stellate cell migration, expression of alpha-smooth muscle actin and collagen, type 1, alpha 2. Data collected from the in vitro model can be integrated into a database with access to related chemical, bioactivity, preclinical and clinical information uploaded from external databases for constructing predictive models.
Introduction
Drug-induced liver injury (DILI), poor pharmacokinetic (PK) properties, as well as limited efficacy have historically been common causes for termination of compounds early in clinical trials. The poor concordance between animal testing and clinical hepatotoxicity is also well known. 1 In the past two decades, the pharmaceutical industry has applied 2D phenotypic and molecular-based in vitro assays, broad spectrum proteomics, metabolomics and toxicogenomics screening to address the challenge. These in vitro approaches were expected to lessen reliance on animal models by providing predictions of toxic liabilities, as well as serving as models for disease. However, these early approaches have only had limited success as predictive tools, but have been useful in early, high throughput, safety profiling and as tools to understand mechanisms of toxicity (MOT). 2 There are now two major drivers for creating better human, in vitro models of hepatotoxicity and liver diseases that address the ''fit for purpose'' criteria used in the pharmaceutical industry: (1) high throughput, human, 2D and 3D, live, physiological liver models in the microplate format that can be used in early safety and efficacy profiling of relatively large numbers of compounds; and (2) human, 3D, live, biomimetic, microfluidic models that exhibit the physiological impact of continuous flow on organ functions; long-term (at least 28 days) functioning for modeling diseases and characterizing chronic toxicity; as well as compatibility for microfluidic coupling, with proper scaling, of multiple organs-on-chips, such as a gut, liver, and kidney, to model partial human functions such as ADME-TOX. [2] [3] [4] [5] In addition, the microfluidic devices can be used to test more challenging MOT, as well as complex disease models studied over an extended period of time where flow is critical. [6] [7] [8] For the high throughput fit for purpose driver, simple cytotoxicity assays have historically been used to assess potential risk. Commonly used cytotoxicity indicators include LDH leakage, live/dead dyes such as Neutral Red, MTT, fluorescent dyes such as 5-Chloromethylfluorescein Diacetate (CMFDA) or Calcein AM and intracellular ATP. 9 Although simple cytotoxicity assays are often used to rank order compounds by overall toxicity risk and to eliminate highly toxic compounds, the assays can have higher levels of false positive and negative rates when compared to multiplexed analysis, which has limited their acceptance as stand-alone criteria for selecting candidate compounds. [10] [11] [12] The combined use of primary hepatocytes, MOT measurements and estimations of total exposure have proven moderately successful for predicting human hepatotoxicity. 12, 13 However, it is clear that ''silent'' toxic agents still pass through these profiles while some safe candidate compounds might be eliminated before additional animal testing. 12, [14] [15] [16] [17] Recently, there has been significant progress in creating human, live, 3D models of the liver in the microplate format that should serve the higher throughput and physiological relevance criteria. 6, 7 It is expected that these models will continue to evolve in performance.
A valuable human, 3D, live, biomimetic, microfluidic model requires the combination of: a biologically relevant matrix material to support a 3D multicellular human microenvironment; all cell types required for organ functionality, media formulations to provide specific organ nutritional and hormonal needs; flow through media to provide the physiologically relevant flow stimulation, drug exposure, sample oxygenation, replenishment of nutrients, and removal of waste products to improve the performance of the model; and a device design that is robust, reproducible, and is expected to be cost-and time-effective when compared with animal testing. When combined with real-time mechanistic readouts, such models are expected to exhibit improved responsiveness to toxic agents and disease processes. Approaches that combine these elements are described as microphysiological systems, ''organs-on-achip'' or organoids. 18, 19 This paper reports on the construction of a first generation design for a human, 3D, four-cell, microfluidic model of the liver in a microfluidic device that addresses most of the optimal characteristics of a microphysiological system (Table 1 ). Figure 1 places this model in the context of a platform that integrates multiple data types to ultimately enable predictive modeling. This liver model is constructed using three human, non-parenchymal cell lines (NPCs) and a single lot of cryopreserved human parenchymal hepatocytes. The results indicate that the sequentially layered cells ''self-assemble'' into a layered tissue-like architecture with many of the organizational and functional features of the liver sinusoidal unit. A portion of the cells in the SQL-SAL are transduced with fluorescent protein biosensors that are incorporated into the genome of the hepatocytes and NPCs, here referred to as sentinel cells. The biosensors in the microfluidic device allow capture of real-time, functional readouts with a confocal high content analysis (HCA) imaging system. The SQL-SAL maintains stable liver function for up to one month and is used here to demonstrate acute and sub-chronic liver injury including direct induction of apoptosis, induction of apoptosis by immune-mediated toxicity, and an early indication of the activation of a fibrosis response. The combination of live cell monitoring of physiological processes, a database to manage, analyze, and model the data, as well as direct access to related chemical, bioactivity, preclinical, and clinical information from external databases, provides an integrated microphysiological platform for assessing human toxic liabilities, as well as efficacy of experimental compounds for liver diseases. This is the first step in creating an optimal platform for stand-alone liver toxicity and disease modelling, as well as coupling with other organs-on-chips. Table 1 also addresses the planned evolution of the platform.
Materials and methods

Cell sources
A selected lot of cryopreserved primary human hepatocytes found to have >90% viability and re-plating efficiency post thaw, was obtained from Life Technologies (Grand Island, NY, USA). EA.hy926 human umbilical vein cell line and U937 human histocytic lymphoma (human monocyte) cells were obtained from ATCC (Manassas, VA, USA). LX-2 human stellate cells were generously provided by Martin Yarmush, Mass General Hospital and are also available from EMD Millipore (Billerica, MA, USA). The EA.hy926cell is a fusion product of the HUVEC and A549 cells. EA.hy926 cells release monocyte chemoattractant protein 1 (MCP) in response to inflammation and do not require the use of growth modulators (e.g. VEGF to support HUVECs). 20 PMA treatment will differentiate U937 cells into mature macrophages which release various cytokines and chemokines in response to soluble stimuli. In particular, differentiated U937 macrophages release human tumor necrosis factor alpha (TNFa) and IL-6 in response to LPS treatment, a condition reported to induce the immune mediated liver toxic response in vitro and in vivo models. 7, 21 The LX-2 cell is an immortalized human hepatic stellate cell that constitutively expresses key receptors regulating hepatic fibrosis and proliferate in response to PDGF, a prominent mitogen contributing to liver fibrosis. 22, 23 Liver model assembly A single chamber commercial microfluidic device (TEMS single channel device, SCD-47, Nortis, Inc. Seattle, WA, USA) 24 was selected for optical quality for imaging and robust mechanical design. The devices were stored in PBS until use. The interior of the devices was rinsed in absolute ethanol and dried under vacuum prior to protein coating with 100 mg/mL bovine fibronectin and 100 mg/mL rat tail collagen, type 1, alpha 2 in PBS as previously described. 25 Cryopreserved hepatocytes were thawed following the manufacturer recommendations. A portion was incubated 2 h in lentiviral supernatant generated from pCT-mito-GFP (apoptosis biosensor) or pLVX-IRES-puro-HyPer-dmito (hydrogen peroxide biosensor, supplemental materials). Hepatocytes were pelleted at 50 g Â 3 min, resuspended at 2.5 Â 10 6 hepatocytes/mL in Williams E medium supplemented with 5% fetal bovine serum (Cellgro, Manassas CA), 100 mg/mL Penicillin Streptomycin (HyClone, Logan, UT), and 2 mM L-glutamine and injected into the interstitial compartment of the device for overnight incubation at 37 C to allow adherence and spreading. A mixture of 2.0 Â 10 6 EA.hy926 cells/mL and 1.6 Â 10 6 U937 monocytic cells/mL (see supplemental materials for details of cell characterization and differentiation) in DMEM (Gibco, 10% FBS, 1 Â penicillin/streptomycin) was then injected on top of the attached hepatocytes, incubated for 2 h at 37 C before the final injection of 0.2 Â 10 6 LX-2 cells suspended in 1 mL of a 2.5 mg/mL solution of pH 7.2 rat tail collagen/10 mM HEPES/HBSS. The devices were inverted for 1 h at 37 C during collagen polymerization to ensure an initial spatial separation of hepatocytes and stellate cells. The devices were re-inverted to their normal orientation and incubated overnight to allow stabilization of the model before initiating 5 mL/h perfusion with hepatocyte maintenance media (HMM, Life Technology, Grand Island, NY, USA) supplemented with 100 nM dexamethasone at 37 C in 5% CO 2 . The density of each cell type and perfusion rate was determined by use of allometric scaling as presented in Table 2 . Determination of flow characteristics in the devices using fluorescent tagged dextran particles is presented in the supplemental materials ( Figure  S1 , Supplementary material). Z-plane images in SQL-SAL devices containing biosensor expressing hepatocytes, stellates, and endothelial cells were collected by confocal HCA imaging to construct a spatial model of the distribution of cells on Day 0 and Day 7. Images were collected starting 200 mm above the attachment surface and serial sectioning down every 10 mm from 200 to 0 mm.
Device testing
Troglitazone, nimesulide, caffeine, trovafloxacin, levofloxacin, LPS and methotrexate (all from Sigma, St Louis, Mo) were administered into the devices as 1% DMSO solutions Database to manage and analyze data -supports results from imaging, biochemistry and MS, and provides tools for modeling human PK/PD, toxicity and efficacy Partial, current database support all three data sources and has capability for managing reference clinical trial and post-marketing data to support modeling
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in HMM at the final concentrations. To achieve testing of up to the recommended 100 Â C max for in vitro liver systems, 26 1.0% DMSO final concentration was used to improve compound solubility. 1.0% DMSO is on the high end of published concentrations, 7,27-29 but the negative control, caffeine in 1.0% DMSO as well as DMSO alone, had no impact on the parameters measured in the devices. The flow was temporarily halted to allow imaging of each device using the GE IN Cell 6000 (GE LifeSciences, Piscataway NJ, USA) equipped with an environmental chamber to maintain 37 C and 5% CO 2 (see below, HCA imaging and analysis). Flow was re-established in the devices after image collection.
Image and efflux media collection
Drug exposure by perfusion was initiated (day 0) following the two days to assemble and stabilize the model. Images 
Efflux media collection and biochemical measurements
Albumin was measured using an enzyme linked immunosorbent assay (Bethyl Laboratories, Montgomery, TX, USA). LDH (CytoTox 96, Promega, Madison, WI, USA) and urea nitrogen (Urea Nitrogen Test, Stanbio Laboratory) was measured using colorimetric assays. Human TNF-a chemiluminescent ELISA was performed as described by manufacturer guidelines (ThermoFisher, Pittsburgh, PA, USA).
All biochemical assays performed on the efflux media were performed in 384 well microplates according to manufacturer's instructions with the exception of the blood urea nitrogen (BUN) assay, which was modified from the manufacturer's protocol by reconfiguring for a 384 well microtiter plate and increasing the incubation of reactants from 60 to 90 min at 60 C before reading. All biochemical assays were conducted on 10 mL of media for each readout and measured on a SpectraMax M2 (Molecular Devices, Sunnyvale, CA, USA) microtiter plate reader. All sample results were calculated by interpolation of sample values from standard curves performed in parallel.
Drug metabolism measurements
Hepatocyte maintenance media supplemented with 5 mM testosterone, 10 mM diclofenac or 10 mM phenolphthalein, and 10 mM 7-ethoxyresorufin (EROD) were perfused through two or more test devices on days 10-12, 14, or 23, respectively. The efflux media was collected over a 24-h period. The drug metabolites were extracted from collected efflux media (Supplementary material) and measured using a Waters Acquity UPLC (Milford, MA, USA) using a C18, 1.7 mm, 2.1 Â 100 mm reversed-phase column. Separation was carried out in an acetonitrile:water (0.1% formic acid) gradient using conditions presented in Table  S1 , Supplementary material. Detection of the metabolite peak was achieved in the positive ion mode with a TSQ Quantum Ultra Mass Spectrometer (ThermoFisher, Pittsburgh, PA, USA), interfaced via an electrospray ionization (ESI) probe (Supplementary material). The metabolite from EROD was measured directly in efflux media on a fluorescent spectrophotometer, as described in the Supplementary material.
Bile efflux testing
Hepatocytes in control devices were tested for normal canalicular efflux of CMFDA at days 10 and 21. Troglitazone inhibition of canaliculi efflux was demonstrated with day 10 devices. Briefly, the devices were perfused with HMM containing either vehicle (1% DMSO) or 50 mM troglitazone for 30 min. CMFDA (Life Technologies, Grand Island, NY) was prepared at 1 mM in HMM and added as a bolus into the assembled device. The devices were removed from perfusion apparatus and placed on the IN Cell 6000 HCA instrument for collection of 488/525 nm (ex/em) images at 10-min intervals over 1 h.
HCA imaging and analysis
All images were collected with a 10Â or 20Â objective using the IN Cell 6000 in confocal mode detailed in Supplementary material. The protocol was configured to collect images at 488/525 nm (ex/em, green channel) and/or 561/605 nm (ex/em, red channel) on 25 or 90 fields with a 10 Â (0.45 N.A) or 20 Â (0.45 N.A.) objective, respectively. These protocols imaged the entire cell attachment surface area. The images collected from the central region of the chamber were used for analysis (10 images at 20Âand 27 images at 10Â, Figure 2(b) ).The aperture slits were set to 1.47 and 0.85 Airy units for the 10Â and 20Â objectives, respectively. The apoptosis biosensor (Supplementary material) in hepatocytes was imaged in the green channel and analyzed using two different application methods in MetaXpress 4 software (Molecular Devices, Sunnyvale, CA, USA). (a) The multi-wavelength cell scoring application module was used to quantify changes in cell average fluorescence intensity as the indicator of apoptosis; and (b) the integrated morphometric module was used to quantify changes in cellular area of hepatocytes expressing the apoptosis biosensor. The ROS biosensor was measured as the time-dependent increase in cellular intensity at 488/525 nm (ex/em) reflecting the increase in ROS. Additional imaging processing details are provided in the Supplementary material. Details on the development and quantitation of biosensors in sentinel cells will be published elsewhere.
Indirect immunofluorescence labeling and quantitation
Relative protein expression of human alpha-smooth muscle actin (alpha-SMA) and collagen type 1, alpha 2 (COL1A2) protein in LX-2 cells transduced with pLVX-IRES-mito-mKate2 biosensor (to identify the cells) was quantified on day 21 in paraformaldehyde fixed devices using standard indirect immunofluorescence methods (Supplementary material). The expression of alpha-SMA or COL1A2 protein was quantified as the ratio of the average cellular intensity of the respective antibody label in the stellate to the non-stellate cell population using Fiji (ImageJ, Supplementary material).
Statistics
Differences in drug and control population measurements reported as ''significant'' have a p 0.05, as determined by application of a t-test with the assumption of equal variance. Human liver microphysiology platform 105   ...................................................................................................................... ....
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Results
Structure, long-term health, and normal function
The uniformity of media perfusion throughout the entire model was evaluated by time-lapse imaging of a bolus injection of fluorescent dextran (10 kD), which indicated consistent media exchange across and through the chamber (Supplementary material, Figure S1 ). The cellular organization and formation of hepatic cords by day 7 in the SQL-SAL were defined by confocal HCA (Figure 2(a) and (b) ). Transmigration and reorganization of endothelial and stellate cells into a layered tissue proximal to the cords was quantified by counting fluorescent protein biosensor labeled cells in 3D image stacks acquired on day 7 (diagrammed in Figure 2(c) and (d) ). A partial sinusoidal structure was attained by Day 7.
LDH leakage was stable in the devices during the 4-week incubation period, following an initial decrease in the efflux media levels on days 0-2 ( Figure 3a) . Albumin production was retained at a stable level during the ca. one month long testing (Figure 3b ) and was consistently higher than in static culture (Figure 3b) as previously reported. 30, 31 In addition, the rates of albumin production in the SQL-SAL model were found to be comparable to previously published reports. 7 Urea synthesis was found to be comparable to some published findings but lower compared to other published findings. 7, 32 In addition, we found urea synthesis declined by day 25. Expression of the cytochrome C apoptosis biosensor increased from day 0 to 10, then stabilized for at least 28 days (Supplementary material, Figure S2 ).
The LC MS/MS was used to identify 6-b hydroxytestosterone (Cyp 3A4 testosterone metabolite), phenolphthaleinglucuronide (phase 2 phenolphthalein conjugate), and 4-hydroxydiclofenac (Cyp 2C9 diclofenac metabolite) extracted from efflux media in SQL-SAL devices perfused on days 10, 12, and 14, respectively (Table 3) . Resorufin, the fluorescent product driven by Cyp 1A1/2 metabolism of 7-ethoxyresorufin (EROD) was identified in the efflux media in a SQL-SAL device perfused on day 23 with 10 mM EROD ( Table 3 ). The specific cytochrome P-450 isoenzyme or conjugation reaction is consistent with published findings. [33] [34] [35] [36] [37] [38] The retention time, parent to daughter fragmentation product, and mass area under the curve for the metabolites are presented (Table 3 ). Only the identification of the metabolite is reported, as the quantitative analysis of drug and metabolite is limited by the presence of PDMS, a material known to adsorb some hydrophobic compounds. 39 
Toxicity testing
The literature on lentiviral transduction with reasonable expression levels indicates that cellular functions are not impacted [40] [41] [42] [43] and we found no differences in the measured responses of HepG2 cells, transduced and non-transduced under treatment conditions that induced oxidative stress (unpublished data). Overt cytotoxicity, measured as LDH release from the SQL-SAL under continuous perfusion, was found on day 4 at 180 mM (30 Â C max ) troglitazone and delayed until day 13 at 28 mM (4 Â C max ) troglitazone compared to 600 mM (100 Â C max ) caffeine used as the negative control (Figure 4a ). The higher troglitazone concentration resulted in a sharp decrease in albumin and urea starting at day 1 of treatment, which was distinct from a gradual decrease of albumin and urea with 28 mM troglitazone versus caffeine control (Figure 4 Figure S3 ).
The induction of apoptosis, as measured by loss in the intensity of the cytochrome C biosensor in the mitochondria in sentinel cells, began on day 1 and on day 10 in the liver devices that received 180 mM and 28 mM troglitazone, respectively (Figure 5a ). The time-dependent loss of mitochondrial cytochrome C biosensor was evident in images acquired over time ( Figure 5(b) and (c) ). There was no appreciable effect of 600 mM caffeine on induction of the hepatocellular apoptosis biosensor over the four-week treatment (Figure 5a ). Further characterization of troglitazone-induced hepatocellular apoptosis was performed using a mitochondrial-targeted ROS biosensor that indicated an increase in ROS when measured over 24 h (Figure 5d) . Images from the real-time readout also demonstrated increased ROS biosensor fluorescence ( Figure 5 (e) and (f)). Then 210 mM nimesulide (10 Â C max ) was used as a second hepatotoxic drug and produced a rapid increase of Figure 3 Long-term health and stability of hepatocytes in the SQL-SAL. (a) Lactate dehydrogenase (LDH) leakage measurements in efflux media are stable from day 3 to 28. (b) Albumin output in the efflux media is relatively stable and physiological for at least 25 days and is elevated relative to that measured in static co-cultures. Although urea output is stable for at least 21 days and elevated relative to static co-cultures, it is lower than most published levels and declines by day 25. Results presented as mean AE SD from 3 (days 3, 10, and 17) or 4 devices (days 7, 13, and 25) or three transwells Vernetti et al. Human liver microphysiology platform 107 apoptotic hepatocytes, with decreases in albumin, urea and a rapid release of LDH ( Figure S4 , Supplementary material).
To investigate immune-mediated hepatotoxicity in the SQL-SAL, differentiated U937 cells were used as surrogate Kupffer cells. The PMA differentiated immune cells released TNF-alpha in plate cultures in response to LPS exposure (Figure 6a ). Drug challenge with 200 mM trovafloxacin (40 Â C max ) or 600 mM levofloxacin (38 Â C max ), with 1 mg/mL LPS, was used to investigate hepatotoxic response in a pro-inflammatory state. Increased LDH leakage was evident at day 3 in devices co-incubated with 200 mM trovafloxacin and LPS (trovafloxacin þ LPS), but not in devices co-incubated with 600 mM levofloxacin and LPS (levofloxacin þ LPS) (Figure 6b) . A significant decrease in hepatocyte area (condensation) was measured as a potential real-time, read-out for hepatocellular injury. A positive correlation between trovafloxacin þ LPS treatment and decrease in hepatocyte area with increased propidium iodide uptake was established from static transwell, four cell liver cultures ( Figure S5, Supplementary material) . A significant time-dependent decrease in hepatocyte cell area was measured after day 3 in 200 mM trovafloxacin þ LPS indicative of apoptosis, while 600 mM levofloxacin þ LPS did not induce apoptosis (Figure 6c) . Interestingly, Levofloxacin þ LPS exhibited an increase in hepatocyte area indicating that some impact on the hepatocytes other than apoptosis occurred. This observation will be followed up with more experiments in the future. Taken together, these findings are in agreement with rodent inflammatory models that have been developed to mimic human findings 44, 45 ; however, this in vitro model is human and the changes can be analyzed dynamically.
Disease model application
To explore the potential application of the liver model to elucidate fibrotic disease, the immortalized human stellate cells (LX-2) transduced with a biosensor to enable the tracking of cell division and movements were monitored for 21 days by confocal HCA. Over this time, the stellate cells transmigrated from an initial uniform distribution throughout the space above the hepatocytes into open spaces between the hepatic cords and into a layer just above the hepatic cords (Figure 7a) . Furthermore, when the stellate cells contacted the hepatocytes, there was an increase in (Figure 7b) . A hallmark of stellate cell transactivation from the vitamin A storage precursor into collagen depositing myofibroblasts is an increase in the expression of alpha-SMA. 46, 47 Our results showed the stellate cells actively expressed increased levels of human COL1A2 and alpha-SMA in response to 30 nM methotrexate treatment over 21 days (maximum tolerated concentration of 100 nM determined in LX2 cultures; data not shown) (Figures 7(b) and 8 ).
Discussion
Although many in vitro models have been used to detect hepatotoxicity, pharmacokinetic properties and efficacy, none have yet successfully recapitulated the complex interactions between the different cell types, cell-to-cell signaling, flow within the liver, as well as oxygen and nutrient zonation ( Table 1) . Many of the in vitro models have proven capable of identifying the direct action of toxicants on the hepatocytes or have been found useful to identify the putative pathways and mechanisms of toxicity that have been linked to clinical hepatotoxicity, but they have had less success in predicting adverse clinical events or serving as models of liver diseases. 13, 14, 48 The work described herein demonstrates progress towards an improved physiological model system that will continue to evolve with increased functionality (Table 1) . We have combined a very simple microfluidic device, 3 human, non-parenchymal cell lines together with primary human hepatocytes as the base-line cell system, a collagen matrix, a sequentially layered, selfassembly construct (SQL-SAL) and flow to create a robust and reproducible, generation one system with reasonable structure and functionality.
Despite the use of in vitro hepatotoxicity testing in the pharmaceutical industry to reduce the numbers of compounds with human toxic liabilities, DILI remains the leading cause of acute liver failure in the USA [49] [50] [51] and the field continues to rely on animal models of disease where the concordance with humans is low. Therefore, there has been a drive to construct more physiologically relevant, human, 3D ''organ'' models with various levels of complexity, including multiple liver cell types, longer-term viability, flow stimulation, and integrative analysis of multiplexed experimental data using computational models. 26, [52] [53] [54] [55] [56] [57] [58] The human liver models have in common the goals to: retain important hepatocyte functions; extend culture time to The shift in toxicity is evident as a decrease in hepatocyte area measured in real time and achieved significance (P 0.05) on days 3-10 in the SQL-SAL exposed to 200 mM trovafloxacin (40 Â C max ) with 1 mg/mL LPS. The decrease in hepatocyte area with trovafloxacin coincubated with LPS treatment was correlated with cell death measured by an increase in propidium iodide uptake (see Figure S6 , Supplementary material). LDH and hepatocyte area results are the mean and SD of replicates per treatment group. P-values were calculated between devices treated with levofloxacin plus LPS and trovafloxacin with LPS. Although levofloxacin plus LPS does not induce apoptosis, it does cause an increase in the hepatocyte area. The biological basis for this change will be investigated in the future accommodate chronic exposure studies; incorporate nonhepatocyte cell components to study immune-mediated DILI, fibrosis or other diseases related to the liver; and to employ a variety of genomic, phenotypic, mass spectroscopy, cell biochemical and media secretion-based assays to evaluate liver health and function in response to challenges. 8, 18, 57 The ''fit for purpose'' criteria offers advantages to the scientific and regulatory community, given the examples of high throughput models with reasonable liver functions that have been used to test large numbers of compounds. 6, 7, 59 However, even more physiologically relevant platforms that include continuous flow and more read-outs, are important for more sophisticated investigations of human toxicity and liver disease progression, as well as multi-organ systems.
The present generation SQL-SAL can be maintained for at least 28 days under continuous media perfusion, demonstrated stable metabolic function, including phase 1 and phase 2 drug metabolism for 10-23 days (28-day studies are planned), polarized bile efflux, protein secretion, and responds predictably to known hepatotoxic compounds. The SQL-SAL can be used for the detection of early and specific modes of toxicity, such as apoptosis and ROS generation, via fluorescent protein biosensors. Monitoring drug toxicity and disease progression in a human, 3D, multiple cell-based platform when applied in parallel to the animal tests required before entering human clinical trials, is expected to improve predictions of human risk and drug efficacy. In time, these in vitro models are expected to reduce and ultimately replace animal testing.
An important advantage of the SQL-SAL is having a physiologically active liver model that can be treated and serially interrogated for damage induced by direct or indirect MOT and disease processes, for at least 28 days. For example, direct acting toxic agents such as troglitazone and nimesulide ultimately end in acute cellular necrosis or apoptosis, often as the result of metabolically reactive drug intermediates leading to dose-and time-dependent generation of oxidative stress, via mitochondrial dysfunction or interference with bile flow. 13 Indirect toxicity can be the result of an inflammatory response with cytokine release triggered by sub-acute hepatocyte damage by drugs such as trovafloxacin. 60 The release of cytokine mediators intensifies the hepatocellular injury, which, if not reversed, will ultimately leads to fatty liver or fibrosis and loss of liver function. 61 More complex interactions between the cell types were demonstrated in the SQL-SAL by methotrexate-induced activation of alpha-SMA and COL1A2 positive stellate cells as an early indication of a fibrotic injury response. Although the progression and severity of the methotrexate fibrotic response reported from several clinical studies is conflicting, it is accepted that drug-damaged hepatocytes and immune cells can release molecular modulators that induce the differentiation of stellate cells into myofibroblasts which ultimately leads to hepatic fibrosis. [62] [63] [64] [65] [66] [67] In addition, we found alpha-SMA expression was increased in hepatocytes under methotrexate treatment. Previous reports of alpha-SMA expression in hepatocytes resulting from the transition from epithelial to mesenchymal like morphology and mesenchymal marker expression have been inconsistent. Knock out studies in mice suggest that hepatocytes do not undergo the epithelial-mesenchymal transition (EMT) or express alpha-SMA during the fibrotic response. 68 However, recent evidence in the rodent supports the EMT in hepatocytes and the increased alpha-SMA expression. 69 In either case, the protein expression profile found in stellate cells in the SQL-SAL is consistent with the early activation of a fibrotic response. The extent and duration of the fibrotic response will be evaluated in more depth in follow-up studies.
The examples presented here for toxicity associated with troglitazone, nimesulide, trovafloxacin and methotrexate serve to describe the complexity of interactions between cell types and multifactorial initiating events in the development of liver injury or disease. The initial results in the Human liver microphysiology platform 111   ......................................................................................................................... . SQL-SAL demonstrate that differentiated cell and tissue-like functions are occurring in an interacting and interdependent physiological environment. At the present time, we are testing a number of known hepatotoxic and non-hepatotoxic compounds as well as paired sets of structurally related compounds of which one member of the pair exhibits hepatotoxicity while the other does not. These studies will be used to acquire a larger data set with which to build predictive models using our MPS-Db database ( Figure S6, Supplementary material) . A detailed characterization of the MPS-dB will be published elsewhere (Gough et. al., in preparation).
The SQL-SAL can detect early and specific modes of toxicity, e.g. apoptosis and ROS; with the use of fluorescent protein biosensors in ''sentinel'' cells with 3D, time series image analysis, an approach that highlights the value of integrated fluorescence biosensors in reporting mechanistic toxicity. Current efforts seek to characterize the use of a broader set of biosensors to determine additional clinically important modes of toxicity and liver disease progression. 70 We are also expanding the SQL-SAL for disease studies through the use of normal and diseased iPS-derived human hepatocytes and a variety of liver disease models. Finally, the differences in metabolic activity between the liver zones are often the cause of toxicity. 70 . A future version of the SQL-SAL will implement zonation to enable the comparison of zone 1 and zone 3 responses in Cyp expression, glutamate synthetase expression, as well as acetaminophen toxicity.
Future developments
The present SQL-SAL maintains major physiological functions for at least 28 days. The SQL-SAL can be used as a stand-alone liver model and when appropriately sized (scaled), integrated with other organ models. 71 There are a number of developments that will be implemented in the next generation SQL-SAL to further improve the physiological value of the liver model (Table 1 ). In particular, we will employ iPS-derived human hepatocytes with a range of normal and disease genomic backgrounds that are now being fully characterized, employ liver specific endothelial cells to optimize the biology, employ matrix-coated plastic, transition to microfluidic devices without PDMS to optimize the use with hydrophobic drugs and biologics, and employ a range of scales and total device volumes to optimize for specific applications. In addition, the SQL-SAL will be used in conjunction with a database that can not only manage, analyze, and model data, but can also access published bioassay, chemical, pre-clinical and clinical findings from public and private databases to enable predictive modeling of human hepatotoxicity risk and various models of disease progression.
A particularly valuable contribution of MPS models in the future will be the inclusion in drug discovery and development programs based on quantitative systems pharmacology (QSP). 72 QSP is an iterative process of computational methods and experimental approaches that is rooted in patient data. The development of a mathematical model of the experimental system is used to suggest new experimental steps. The inclusion of iPS-derived cells from patients with genetic and disease backgrounds in physiologically relevant experimental models will ''personalize'' the drug discovery and development process. The development of MPS models is an evolutionary process, but with revolutionary potential to change how we investigate human diseases and toxicology. 19 Authors' contributions: All authors participated in the design, interpretation of the studies, analyses of the data and review of the manuscript. LV, NS, RB, and RDB conducted the experiments. TYS ran statistical analysis. LV, NS, AG, and DLT wrote the manuscript.
